PT-141

• Hypoactive Sexual Desire Disorder (HSDD) in women (FDA-approved)
• Low libido and sexual arousal issues in men and women
• Alternative treatment for erectile dysfunction (especially non-responders to PDE5 inhibitors)
• Enhancement of sexual satisfaction and motivation
• Off-label use in premenopausal women with reduced sexual drive

Melanocortin Receptor Agonism: Binds to MC3-R and MC4-R in the hypothalamus to stimulate sexual arousal centers
Central Nervous System Targeting: Unlike PDE5 inhibitors, PT-141 acts via the CNS, not the vascular system
Neurotransmitter Modulation: Enhances dopamine and oxytocin signaling to improve desire and pleasure response

1. Female Sexual Dysfunction – Phase 3 Trial

• Findings: Improved sexual desire and satisfaction vs placebo in women with HSDD
• PMID: https://pubmed.ncbi.nlm.nih.gov/31675872/

2. HSDD in Women – Clinical Trial

• Findings: Increased sexual function; well-tolerated with nausea as the most common side effect
• PMID: https://pubmed.ncbi.nlm.nih.gov/29362639/

3. Safety and Efficacy in HSDD

• Findings: Low incidence of serious side effects, effective in improving sexual desire
• PMID: https://pubmed.ncbi.nlm.nih.gov/30703677/

4. RCT in Women with HSDD

• Findings: Significant improvement in sexual satisfaction and libido compared to placebo
• PMID: https://pubmed.ncbi.nlm.nih.gov/30263140/

5. Sexual Desire in Men

• Findings: Demonstrated benefits in male libido and erectile response, even in non-responders to traditional ED meds
• PMID: https://pubmed.ncbi.nlm.nih.gov/25345518/

6. Female Sexual Arousal

• Findings: Pre-sexual activity use led to greater arousal and satisfaction in women with HSDD
• PMID: https://pubmed.ncbi.nlm.nih.gov/30763424/

7. Erectile Dysfunction in Men – Preclinical/Clinical Studies

• Findings: Central nervous system effects show promise as alternative ED therapy
• PMID: https://pubmed.ncbi.nlm.nih.gov/24062352/